Antibe Provides Scientific Report on Its Recently Completed Phase 2B Study Showing Unequivocal Gastrointestinal Safety of ATB-346 Pharmaceutical Investing
Cotinga Pharmaceuticals Reports Fiscal 2018 Fourth Quarter and Full Year Financial and Operating Results Pharmaceutical Investing
Yescarta (Axicabtagene Ciloleucel) Receives European Marketing Authorization for the Treatment of Relapsed or Refractory DLBCL and PMBCL Pharmaceutical Investing
Sienna Biopharmaceuticals Announces Results from First-in-Human Study of SNA-125 in Psoriasis and Continued Progression to Phase 2 Biotech Investing
Pernix Therapeutics Announces Ruling in Patent Litigation Concerning Zohydro ER with BeadTek Pharmaceutical Investing
Amarin’s REDUCE-IT Clinical Study Now Positioned to be Next Large Cardiovascular Outcomes Study to Report Results Biotech Investing
Shire Announces FDA Approval of TAKHZYRO (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema Biotech Investing
Intellia Therapeutics Presents Progress in Lead In Vivo Program at Cold Spring Harbor Laboratory’s Fourth Meeting on Genome Engineering: The CRISPR-Cas Revolution Genetics Investing
Immunomedics Announces Fourth Quarter and Fiscal Year 2018 Results and Provides Corporate Update Biotech Investing
